The Isg15 Knockout MIN6 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population derived from the MIN6 mouse insulinoma pancreatic beta cell line, engineered for targeted disruption of the Isg15 gene. This polyclonal knockout product comprises a diverse pool of cells carrying heterogeneous modifications at the Isg15 locus, providing a robust loss-of-function model without the selective pressure of single-cell cloning. The model is supplied as a ready-to-use polyclonal population, designed to support investigations of ISG15-dependent mechanisms in beta cell biology, antiviral immunity, and immune-mediated diabetes. Researchers benefit from the physiological relevance of the MIN6 background combined with effective Isg15 gene disruption, facilitating reproducible functional studies in insulin-secreting cells.
The host MIN6 cell line was originally derived from a transgenic mouse insulinoma and retains key characteristics of mature pancreatic beta cells, including glucose-stimulated insulin secretion and expression of beta cell-specific transcription factors. MIN6 cells are widely employed as a model for studying beta cell function, glucose homeostasis, and the molecular pathogenesis of diabetes. Their robust insulin secretory response and sensitivity to inflammatory cytokines make them particularly valuable for dissecting the interplay between immune signaling and beta cell survival. In the context of type 1 diabetes research, MIN6 cells recapitulate important aspects of interferon-driven beta cell destruction, positioning them as a relevant platform for exploring the role of ISG15.
Isg15 encodes a ubiquitin-like protein that is covalently conjugated to target lysine residues through an ISGylation cascade, a process with well-established roles in antiviral immunity. The conjugation system involves the E1 enzyme UBE1L, the E2 enzyme UbcH8, and the E3 ligase HERC5, while deconjugation is mediated by the protease USP18. ISG15 is strongly induced by type I interferons (IFN-?? and IFN-??) via JAK-STAT signaling, where activated STAT1, STAT2, and IRF9 bind to interferon-sensitive response elements. Similarly, transcription factors IRF3, IRF7, and NF-??B can drive Isg15 expression. Once conjugated, ISG15 modifies a range of substrates including RIG-I, MDA5, and components of the IFNAR signaling complex, thereby modulating downstream cytokine responses and antiviral effectors. In the beta cell milieu, ISG15 may influence the balance between survival and apoptosis during autoimmune attack.
The application of Isg15 knockout in MIN6 polyclonal cells provides a powerful tool for examining ISG15-dependent pathways in pancreatic beta cells under physiologically relevant conditions. Loss of ISG15 is expected to alter the cellular response to interferon stimulation, potentially affecting ISGylation of key immune signaling proteins and downstream cytokine production. This model is particularly relevant for type 1 diabetes research, where interferon-driven inflammation is implicated in the selective destruction of beta cells. By comparing knockout and wild-type MIN6 populations, investigators can assess the contribution of ISG15 to IFN-??- or IFN-??-induced apoptosis, uncover modified substrates in the ISGylation pathway, and explore interactions between ISG15 and interacting factors such as USP18, which also regulates interferon sensitivity.
This product supports a wide array of experimental applications, including the study of antiviral response mechanisms, immune signaling in beta cells, and ISGylation dynamics. Representative assays that can be performed with these cells include western blotting for ISG15 and ISGylated proteins to monitor conjugation activity, RT-qPCR for Isg15 transcript levels, immunofluorescence to visualize ISG15 localization, flow cytometry for beta cell identity markers, and cytokine-induced apoptosis assays using type I interferons. Additionally, glucose-stimulated insulin secretion assays enable functional assessment of beta cell physiology in the absence of ISG15. These polyclonal knockout cells are also suitable for drug testing aimed at modulating ISGylation or interferon signaling in the context of autoimmune diabetes. For technical inquiries or to discuss customized applications, please contact Ascent Research.
